Detection of twelve nucleotides insertion in the BCR-ABL kinase domain in an imatinib-resistant but dasatinib-sensitive patient with bi-phenotypic acute leukemia.
作者信息
Hayette Sandrine, Chabane Kaddour, Tchirkov Andrei, Berger Marc G, Nicolini Franck E, Tournilhac Olivier
出版信息
Haematologica. 2009 Sep;94(9):1324-6. doi: 10.3324/haematol.2009.007864.
Abstract
摘要
相似文献
1
Detection of twelve nucleotides insertion in the BCR-ABL kinase domain in an imatinib-resistant but dasatinib-sensitive patient with bi-phenotypic acute leukemia.
Haematologica. 2009 Sep;94(9):1324-6. doi: 10.3324/haematol.2009.007864.
2
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Blood. 2009 Sep 3;114(10):2037-43. doi: 10.1182/blood-2009-01-197715. Epub 2009 Jun 30.
3
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
Haematologica. 2009 Sep;94(9):1227-35. doi: 10.3324/haematol.2009.006981. Epub 2009 Jul 16.
4
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
Blood. 2009 Sep 3;114(10):2168-71. doi: 10.1182/blood-2009-01-197186. Epub 2009 Jul 9.
5
Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.
Haematologica. 2011 Mar;96(3):360-6. doi: 10.3324/haematol.2010.030999. Epub 2010 Dec 6.
6
ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells.
Leukemia. 2010 Apr;24(4):869-72. doi: 10.1038/leu.2009.300. Epub 2010 Jan 28.
7
Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Expert Opin Investig Drugs. 2007 May;16(5):679-87. doi: 10.1517/13543784.16.5.679.
8
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
Haematologica. 2010 Feb;95(2):232-40. doi: 10.3324/haematol.2009.011452.
9
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
N Engl J Med. 2006 Jun 15;354(24):2531-41. doi: 10.1056/NEJMoa055229.
10
Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leuk Lymphoma. 2010 Feb;51(2):188-98. doi: 10.3109/10428190903452834.
引用本文的文献
1
The Emergence of a Novel Insertional Mutation in the BCR::ABL/p210 Oncogene in B-Cell Acute Lymphoblastic Leukemia (B-ALL) Correlates with the Development of Resistance to Several Tyrosine Kinase Inhibitors.
Acta Naturae. 2025 Apr-Jun;17(2):52-57. doi: 10.32607/actanaturae.27539.
2
Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient.
Ann Hematol. 2025 Feb;104(2):1117-1126. doi: 10.1007/s00277-024-06142-8. Epub 2025 Jan 7.
3
A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.
Int J Hematol. 2011 Feb;93(2):237-242. doi: 10.1007/s12185-011-0766-2. Epub 2011 Jan 25.
本文引用的文献
1
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations.
Mol Cancer Ther. 2008 Dec;7(12):3834-41. doi: 10.1158/1535-7163.MCT-08-0482. Epub 2008 Dec 3.
2
An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy.
J Mol Diagn. 2008 Mar;10(2):177-80. doi: 10.2353/jmoldx.2008.070128. Epub 2008 Feb 14.
3
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
Haematologica. 2008 Feb;93(2):186-92. doi: 10.3324/haematol.11993. Epub 2008 Jan 26.
4
Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.
Haematologica. 2007 Sep;92(9):1238-41. doi: 10.3324/haematol.11369.
5
A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib.
Leukemia. 2006 Nov;20(11):2057-60. doi: 10.1038/sj.leu.2404400. Epub 2006 Sep 28.
6
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.
Leukemia. 2006 Oct;20(10):1767-73. doi: 10.1038/sj.leu.2404318. Epub 2006 Jul 20.
7
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).
Leukemia. 2006 Jun;20(6):1061-6. doi: 10.1038/sj.leu.2404236.
8
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
Blood. 2006 Jul 1;108(1):28-37. doi: 10.1182/blood-2006-01-0092. Epub 2006 Mar 7.
9
Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients.
Leuk Res. 2005 Sep;29(9):1073-7. doi: 10.1016/j.leukres.2005.02.006. Epub 2005 Mar 23.
10
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
J Clin Oncol. 2005 Jun 20;23(18):4100-9. doi: 10.1200/JCO.2005.05.531. Epub 2005 May 2.
Zotero 插件